Astellas Pharma (ALPMY) Earnings Date, Estimates & Call Transcripts → One trade. One ticker. One week. (From Wealthpin Pro) (Ad) Free alpmy Stock Alerts $9.53 +0.03 (+0.32%) (As of 04/22/2024 ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort Interest Earnings SummaryLatest Earnings DateFeb. 5EstimatedActual EPS (Feb. 5) $0.12 Beat By $0.12 Get Astellas Pharma Earnings AlertsEnter your email address below to receive the latest news and earnings results for ALPMY and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueALPMY Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.ALPMY Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad The Bull ReportHealthcare Takes A Big Step Forward With The Help Of AIThe average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.Click here to see why this small company is trusted by the Mayo Clinic Astellas Pharma Analyst EPS EstimatesCurrent Year EPS Consensus Estimate:$0.23 EPSNext Year EPS Consensus Estimate: $0.50 EPSALPMY Earnings Date and InformationAstellas Pharma last posted its earnings data on February 5th, 2024. The reported $0.12 earnings per share (EPS) for the quarter. The business had revenue of $2.86 billion for the quarter. Astellas Pharma has generated $0.00 earnings per share over the last year and currently has a price-to-earnings ratio of 24.4. Earnings for Astellas Pharma are expected to grow by 117.39% in the coming year, from $0.23 to $0.50 per share. Read More Astellas Pharma Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript2/5/2024Q3 2024-$0.12+$0.12$0.17-$2.86 billion11/1/2023Q3 2023$0.17($0.01)($0.18)($0.01)-$2.71 billion 8/1/2023Q2 2023$0.22$0.13($0.09)$0.13-$2.73 billion4/27/2023Q4 2023-$0.15+$0.15$0.49-$2.68 billion2/6/2023Q3 2023-$0.27+$0.27$0.35-$2.85 billion10/31/2022Q2 2023-$0.28+$0.28$0.28-$2.76 billion Get the Latest News and Ratings for ALPMY and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Astellas Pharma and its competitors with MarketBeat's FREE daily newsletter. 8/1/2022Q1 2023-$0.10+$0.10$0.10-$2.95 billion4/27/2022Q4 2022-($0.04)($0.04)($0.04)-$2.62 billion2/2/2022Q3 2022-$0.34+$0.34$0.39-$3.00 billion10/29/2021Q2 2022-$0.20+$0.20$0.20-$2.96 billion7/30/2021Q1 2022-$0.15+$0.15$0.15-$2.98 billion4/27/2021Q1 2021$0.22($0.06)($0.28)($0.06)-$2.91 billion Astellas Pharma Earnings - Frequently Asked Questions When did Astellas Pharma announce their last quarterly earnings? Astellas Pharma (OTCMKTS:ALPMY) last announced its quarterly earning data on Monday, February 5, 2024. Learn more on ALPMY's earnings history. How much revenue does Astellas Pharma generate each year? Astellas Pharma (OTCMKTS:ALPMY) has a recorded annual revenue of $11.24 billion. How much profit does Astellas Pharma generate each year? Astellas Pharma (OTCMKTS:ALPMY) has a recorded net income of $742 million. ALPMY has generated $0.00 earnings per share over the last four quarters. What is Astellas Pharma's price-to-earnings ratio? Astellas Pharma (OTCMKTS:ALPMY) has a trailing price-to-earnings ratio of 24.36 and a forward price-to-earnings ratio of 41.43. The price/earnings-to-growth ratio is 1.37. What is Astellas Pharma's EPS forecast for next year? Astellas Pharma's earnings are expected to grow from $0.23 per share to $0.50 per share in the next year, which is a 117.39% increase. More Earnings Resources from MarketBeat Related Companies: BMRN Earnings Date ALNY Earnings Date TEVA Earnings Date GMAB Earnings Date VTRS Earnings Date BGNE Earnings Date MKGAF Earnings Date KRTX Earnings Date RDY Earnings Date SRPT Earnings Date Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: Taiwan Semiconductor Earnings: AI Dominance and Future OutlookCSX Co.: The Railroad Powering Ahead with an Earnings Beat What's Driving Tesla Lower Ahead of its Earnings?Blackrock vs. State Street: Earnings in a Volatile MarketWhat to Expect From the Q1 Earnings Reporting SeasonLululemon Stock Implodes Post Earnings, Guidance Muted Applied Optoelectronics earnings dumper, pain now for gain later? This page (OTCMKTS:ALPMY) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Astellas Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
